ZBeats Receives FDA Clearance for ZBPro Diagnostic v2.0, Supporting ECG Analysis Up to 14 Days

Markets PR Newswire By PR Newswire 16 Sep 2026 02:12 1 min read
ZBeats Receives FDA Clearance for ZBPro Diagnostic v2.0, Supporting ECG Analysis Up to 14 Days

Expanded platform supports wearable patches across diverse recording devices; Company to showcase new capabilities at HRX 2026 in Atlanta. STONY BROOK, N.Y., Sept. 15, 2026 /PRNewswire/ -- ZBeats Inc. today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.